@ecmmcandidaiv.bsky.social
📤 31
📥 5
📝 5
Update on Candida IV study at
#TIMM2025
Still open for registration 🔬🧫🧪 Join now!
3 days ago
0
2
1
Preliminary results of the Candida IV study at
#ISHAM2025
and
#ESCMID2025
Study is still open to join 🔬🥼👩🔬
3 days ago
0
1
0
reposted by
Oliver Cornely
about 1 month ago
Early mycological clearance in uncomplicated candidaemia can improve outcomes, reduce ICU stay, and lower healthcare costs. Timely antifungal therapy is key. Read more:
doi.org/10.1111/myc....
@martinhoenigl.bsky.social
#Candidaemia
#AntifungalTherapy
#InfectiousDiseases
#ICU
#Healthcare
loading . . .
The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice
Invasive candidiasis is a life-threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifunga....
https://doi.org/10.1111/myc.70135
0
11
8
Proud to present the progress of ECMM Candida IV study at
#ISHAM2025
Still open for participation!
@martinhoenigl.bsky.social
8 months ago
0
4
2
Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here:
www.ecmm.info/working-grou...
@martinhoenigl.bsky.social
loading . . .
Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida - ECMM
ECMM Candida IV Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida Observation periods/Timeline Observation period: April 1st, 2024 – September 30th, ...
https://www.ecmm.info/working-groups/2219/
9 months ago
0
5
3
ECMM Candida IV Study is still open for participation Global study on non-albicans candidemia Requirements: 🔬Clinical data + isolates (no limit per site) 📅Apr 2024-Sep 2025 📦Ship isolates in one batch at study end 💰Case-based reimbursement available
@martinhoenigl.bsky.social
9 months ago
0
7
6
you reached the end!!
feeds!
log in
